---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-074775"
form_type: "8-K/A"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2024-03-22T23:59:59+00:00"
generated_at: "2026-06-04T09:06:23.535924+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Homology Medicines: reverse stock split effective March 26; Nasdaq listing approved for combined company

## Summary
- Reverse stock split at 1-for-18 ratio effective at trading open on March 26, 2024; new CUSIP 746964105.
- Stockholders to receive cash for fractional shares based on March 25 closing price.
- Nasdaq Staff approved initial listing application for continued listing of Homology common stock post-merger with Q32.
- Reverse split is part of the merger with Q32 Bio Inc.; Q32 will survive as a wholly owned subsidiary.

## SEC filing metadata
- accession: 0001193125-24-074775
- form_type: 8-K/A
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2024-03-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312524074775/0001193125-24-074775-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312524074775/d817398d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-074775
- JSON: https://secwatch.observer/filing/0001193125-24-074775.json
- Plain text: https://secwatch.observer/filing/0001193125-24-074775.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.